ClinicalTrials.gg
RecruitingNCT05894421Updated Mar 12, 2024

TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

A Phase 1 interventional study of TQB2223 injection+ Penpulimab Injection in Advanced Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Recruiting at 11 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

TQB2223 is a recombinant, fully humanized antibody that binds lymphocyte activation gene-3 (LAG-3) and blocks the LAG-3/ major histocompatibility complex class II (MHC-II) interaction, thus allowing for increased T-cell proliferation and cytokine production. This is a phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and effectiveness of TQB2223 injection in combination with Penpulimab in subjects with advanced cancers.

02

Conditions studied

  • Advanced Cancer
03

In context

Lead sponsor

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. is the lead sponsor of 320 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Evidence of a personally signed and dated document indicating that the patient has been informed of all pertinent aspects of the study;
  • Male or female patient 18 to 75 years of age, an (ECOG) performance status of 0 to 1, and ≥3 months;
  • or cytologically confirmed ;
  • Subjects with advanced malignant tumors who failed standard treatment or lacked effective treatment;
  • Patient has at least one evaluable lesion assessed by 1.1;
  • The main organs function is well;
  • Male or female patient had no plans to become pregnant and voluntarily take effective measures during study period until at least 6 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Concurrent secondary . or other malignancy with no evidence of disease for more than 5 years;
  • History of uncontrolled intercurrent illness;
  • Major surgical procedure, radiotherapy, chemotherapy, or immunotherapy within 4 weeks prior to first dose;
  • Prior treatment targeting LAG-3;
  • Unstable or serious concurrent medical conditions, as assessed by the Investigators, that would substantially increase the risk-benefit ratio of participating in the study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    TQB2223 injection+ Penpulimab Injection

    intravenous injection of TQB2223 injection and Penpulimab injection for one times every three weeks, 21 days as a treatment cycle.

    Drug: TQB2223 injection+ Penpulimab Injection

Interventions

  • DrugTQB2223 injection+ Penpulimab Injection

    Drug page: Penpulimab

    TQB2223 is an anti lymphocyte activation gene-3 (LAG-3) antibody. Penpulimab Injection is an anti-PD-1 antibody.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    DLT is defined as toxicities that meet pre-defined severity criteria of Common Terminology Criteria for Adverse Events (CTCAE) v5.0, and assessed as having a suspected relationship to TQB2223 injection, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (21 days) of treatment.

    Time frame: During the first treatment cycle (21 days).

  2. Maximum tolerated dose (MTD)

    MTD was defined as the highest dose at which dose-limiting toxicity (DLT) occurred in less than 33% of patients.

    Time frame: During the first treatment cycle (21 days).

  3. Objective Response Rate (ORR)

    Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria and Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST) for solid tumors, Lugano 2014 criteria and Lymphoma Response to Immunomodulatory therapy Criteria (LYRIC) for lymphoma.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks.

Secondary outcomes

  1. Percentage of anti-drug antibody (ADA) positive patients

    Percentage of ADA positive patients will be calculated to evaluate immunogenicity of TQB2223.

    Time frame: Pre-dose on Cycle 1, 2, 4, 8 . 30 days and 90 days after the last dose. Each cycle is 21 days.

  2. The area under the curve (AUC)

    The area under the curve (AUC) of serum concentration of TQB2223

    Time frame: 5 minutes, 2 hour, 6 hours, 24 hours, 144 hours and 336 hours after dose on cycle 1 and cycle 3. Pre-dose on cycle 2, 4, 5, 6, 7, 8. Each cycle is 21 days.

  3. Peak concentration (Cmax)

    Maximum observed concentration (Cmax) of TQB2223

    Time frame: 5 minutes, 2 hour, 6 hours, 24 hours, 144 hours and 336 hours after dose on cycle 1 and cycle 3. Pre-dose on cycle 2, 4, 5, 6, 7, 8. Each cycle is 21 days.

  4. Terminal half-life (T1/2)

    The terminal elimination half-life (t 1/2) is the time that takes for the elimination processes to reduce the plasma concentration of the drug in the body by 50 %.

    Time frame: 5 minutes, 2 hour, 6 hours, 24 hours, 144 hours and 336 hours after dose on cycle 1 and cycle 3. Pre-dose on cycle 2, 4, 5, 6, 7, 8. Each cycle is 21 days.

  5. Receptor occupation (RO)

    Receptor occupation (RO) of LAG-3 after administration.

    Time frame: 5 minutes, 2 hour, 6 hours, 24 hours, 144 hours and 336 hours after dose on cycle 1 and cycle 3. Pre-dose on cycle 2, 4, 5, 6, 7, 8. Each cycle is 21 days.

  6. Objective Response Rate (ORR)

    Defined as the percentage of Complete Response (CR) plus partial response (PR) assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 criteria and Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics (iRECIST) for solid tumors, Lugano 2014 criteria and Lymphoma Response to Immunomodulatory therapy Criteria (LYRIC) for lymphoma.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  7. Disease control rate (DCR)

    Defined as the proportion of subjects with CR, PR, or Stable Disease (SD).

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  8. Duration of Response (DOR)

    Defined as the time from first documented response to documented disease progression or death.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  9. Progression-free survival (PFS)

    Defined as the time from the first dose of TQB2223 to the first occurrence of disease progression or death from any cause.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  10. Overall survival (OS)

    Overall survival refers to the time from the first treatment to death from any cause.

    Time frame: From date of the first dose until the date of first documented progression or date of death from any cause, assessed up to 100 weeks

  11. Number of patients with adverse events (AEs)

    Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From the time of informed consent signed to 28 days after the last dose

  12. Number of patients with serious adverse events (SAEs)

    Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: From the time of informed consent signed to 28 days after the last dose

07

Study locations

9 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2023 (actual). Primary completion is estimated for Jan 2025, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2023
First posted
Jun 8, 2023
StartActual
Jun 6, 2023
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2026
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05894421
Responsible party
Sponsor
First posted
Jun 8, 2023
Start date
Jun 6, 2023
Primary completion
Jan 2025 (estimated)
Completion
Jan 2026 (estimated)
Last update
Mar 12, 2024

Study contacts

Li Zhang, Doctor
Contact
zhangli@sysucc.org.cn
86-020-87343458
Qingqing Cai, Doctor
Contact
caiqq@sysucc.org.cn
+86 13798101121

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Penpulimab

Start the discussion